Travere Therapeutics, Inc. (TVTX)

50.19 -2.60 (-4.93%) USD  |  NASDAQ  |  Oct 16, 12:46
More

Travere Therapeutics SG&A Expense (TTM) : 396.39M for June 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 396.39M
March 31, 2026 369.43M
December 31, 2025 337.20M
September 30, 2025 305.01M
June 30, 2025 284.17M
March 31, 2025 272.73M
December 31, 2024 264.12M
September 30, 2024 258.21M
June 30, 2024 260.39M
March 31, 2024 269.65M
December 31, 2023 271.38M
September 30, 2023 264.87M
June 30, 2023 249.49M
March 31, 2023 228.44M
December 31, 2022 209.27M
September 30, 2022 194.26M
June 30, 2022 177.91M
March 31, 2022 159.89M
December 31, 2021 149.88M
September 30, 2021 143.55M
June 30, 2021 139.43M
March 31, 2021 139.44M
December 31, 2020 135.80M
September 30, 2020 127.59M
June 30, 2020 125.42M
Date Value
March 31, 2020 129.42M
December 31, 2019 128.95M
September 30, 2019 127.37M
June 30, 2019 123.70M
March 31, 2019 109.83M
December 31, 2018 103.63M
September 30, 2018 104.32M
June 30, 2018 103.07M
March 31, 2018 106.80M
December 31, 2017 103.45M
September 30, 2017 103.43M
June 30, 2017 102.42M
March 31, 2017 96.79M
December 31, 2016 92.80M
September 30, 2016 66.18M
June 30, 2016 64.64M
March 31, 2016 61.12M
December 31, 2015 56.86M
September 30, 2015 75.58M
June 30, 2015 71.84M
March 31, 2015 63.49M
December 31, 2014 58.73M
September 30, 2014 46.20M
June 30, 2014 30.90M
March 31, 2014 24.16M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
TG Therapeutics, Inc. 296.46M
BioMarin Pharmaceutical, Inc. 1.368B
Vertex Pharmaceuticals, Inc. 2.008B
Viridian Therapeutics, Inc. 151.65M
Krystal Biotech, Inc. 159.89M